Literature DB >> 19673649

Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection.

Barbara H McGovern1, Ellen H Nagami, Christopher E Birch, Melinda J Bowen, Laura L Reyor, Raymond T Chung, Arthur Y Kim.   

Abstract

Treatment of acute hepatitis C virus (HCV) infection leads to a sustained virologic response (SVR) in the vast majority of patients, although the clinical predictors of these favorable responses are not well understood. In chronic infection, the most potent predictor of a SVR is complete viral suppression after 4 weeks of treatment, also known as a rapid virologic response (RVR). However, few patients with HCV genotype 1 infection and high-level viremia ever achieve this benchmark. In 2 separate cohorts of patients with acute HCV infection, we demonstrate that rapid virologic clearance and low-level viremia (HCV RNA level, <400,000 IU/mL) are highly prevalent, regardless of HCV genotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19673649      PMCID: PMC2762747          DOI: 10.1086/605444

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

Authors:  Peter Ferenci; Michael W Fried; Mitchell L Shiffman; Coleman I Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampero Carosi; Daniel Dhumeaux; Antonio Craxì; Monique Chaneac; K Rajender Reddy
Journal:  J Hepatol       Date:  2005-09       Impact factor: 25.083

2.  Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.

Authors:  Donald M Jensen; Timothy R Morgan; Patrick Marcellin; Paul J Pockros; K Rajender Reddy; Stephanos J Hadziyannis; Peter Ferenci; Andrew M Ackrill; Bernard Willems
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

3.  Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

Authors:  Andrea L Cox; Timothy Mosbruger; Georg M Lauer; Drew Pardoll; David L Thomas; Stuart C Ray
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

4.  Outcomes and treatment of acute hepatitis C virus infection in a United States population.

Authors:  Kathleen E Corey; Andrew S Ross; Alysse Wurcel; Julian Schulze Zur Wiesch; Arthur Y Kim; Georg M Lauer; Raymond T Chung
Journal:  Clin Gastroenterol Hepatol       Date:  2006-08-22       Impact factor: 11.382

5.  Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.

Authors:  Etienne Meylan; Joseph Curran; Kay Hofmann; Darius Moradpour; Marco Binder; Ralf Bartenschlager; Jürg Tschopp
Journal:  Nature       Date:  2005-09-21       Impact factor: 49.962

6.  HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.

Authors:  Norah J Shire; Paul S Horn; Susan D Rouster; Sandra Stanford; M Elaine Eyster; Kenneth E Sherman
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

7.  Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I.

Authors:  Rhea Sumpter; Yueh-Ming Loo; Eileen Foy; Kui Li; Mitsutoshi Yoneyama; Takashi Fujita; Stanley M Lemon; Michael Gale
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

8.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

9.  Effects of antiviral therapy on the cellular immune response in acute hepatitis C.

Authors:  Fareed Rahman; Theo Heller; Yuji Sobao; Eishiro Mizukoshi; Michelina Nascimbeni; Harvey Alter; Steven Herrine; Jay Hoofnagle; T Jake Liang; Barbara Rehermann
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

10.  Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection.

Authors:  Barbara H McGovern; Barham K Abu Dayyeh; Raymond T Chung
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

View more
  10 in total

Review 1.  Treatment of acute HCV infection.

Authors:  Jason Grebely; Gail V Matthews; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-22       Impact factor: 46.802

2.  A "one-two punch" leading to hepatitis C seroconversion.

Authors:  Ellen H Nagami; Arthur Y Kim; Christopher E Birch; Melinda J Bowen; Barbara H McGovern
Journal:  Clin Infect Dis       Date:  2010-12-28       Impact factor: 9.079

Review 3.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

Review 4.  Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.

Authors:  Lynn E Taylor; Tracy Swan; Gail V Matthews
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

5.  Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.

Authors:  Jason Grebely; Margaret Hellard; Tanya Applegate; Kathy Petoumenos; Barbara Yeung; Jordan J Feld; William Rawlinson; Andrew R Lloyd; Jacob George; John M Kaldor; Gregory J Dore; Gail V Matthews
Journal:  AIDS       Date:  2012-08-24       Impact factor: 4.177

6.  Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution.

Authors:  Lin Liu; Brian E Fisher; David L Thomas; Andrea L Cox; Stuart C Ray
Journal:  Hepatology       Date:  2012-04-18       Impact factor: 17.425

7.  The spectrum of undiagnosed hepatitis C virus infection in a US HIV clinic.

Authors:  Lynn E Taylor; Julie A Foont; Allison K DeLong; Alysse Wurcel; Benjamin P Linas; Stacey Chapman; Michaela A Maynard; Susan Cu-Uvin; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2014-01       Impact factor: 5.078

8.  Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment.

Authors:  Jacqueline K Flynn; Gregory J Dore; Margaret Hellard; Barbara Yeung; William D Rawlinson; Peter A White; John M Kaldor; Andrew R Lloyd; Rosemary A Ffrench
Journal:  J Gastroenterol Hepatol       Date:  2013-11       Impact factor: 4.029

9.  A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users.

Authors:  Arthur Y Kim; Ellen H Nagami; Christopher E Birch; Melinda J Bowen; Georg M Lauer; Barbara H McGovern
Journal:  Hepatology       Date:  2013-02-15       Impact factor: 17.425

10.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2014-06-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.